lapatinib has been researched along with Esophageal Squamous Cell Carcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, R; Guo, X; Guo, Z; Kang, J; Zhang, H; Zhu, X | 1 |
| Hou, Y; Liu, Y; Xue, L; Zhao, L | 1 |
| Dou, QH; Guo, XF; Li, SS; Liu, D; Zhu, XF | 1 |
| Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X | 1 |
| Aburatani, H; Fukayama, M; Hoshino, H; Hosoya, Y; Ishikawa, S; Lefor, AK; Matsubara, D; Morishima, K; Niki, T; Saito, S; Sata, N; Ui, T; Yasuda, Y | 1 |
1 review(s) available for lapatinib and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Selected updates in molecular and genomic pathology of esophageal cancer.
Topics: Adenocarcinoma; Alphapapillomavirus; Antineoplastic Agents, Immunological; B7-H1 Antigen; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Lapatinib; Papillomavirus Infections; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab | 2020 |
4 other study(ies) available for lapatinib and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gefitinib; Humans; Insulin-Like Growth Factor I; Lapatinib; Protein Kinase Inhibitors; Receptor, IGF Type 1 | 2022 |
Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Esophageal Squamous Cell Carcinoma; Female; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Lapatinib; Male; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; Random Allocation; Receptor, ErbB-2; Transcriptome; Xenograft Model Antitumor Assays | 2013 |
The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fibroblast Growth Factors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lapatinib; Molecular Sequence Data; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor | 2015 |